Next Article in Journal
Oxidative High Mobility Group Box-1 Accelerates Mitochondrial Transfer from Mesenchymal Stem Cells to Colorectal Cancer Cells Providing Cancer Cell Stemness
Previous Article in Journal
Intracrine Formation of Steroid Hormones in Breast Cancer, Epidermal Keratinocyte, Dermal Fibroblast, and Adipocyte Cell Lines Measured by LC-MS/MS
Previous Article in Special Issue
Probiotic Spores of Shouchella clausii SF174 and Displayed Bromelain Show Beneficial Additive Potential
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 3
10.3390/ijms26031191
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model

by
Mitsuki Matsumura
1,
Hisako Fujihara
1,2,*,
Kanna Maita
1,
Moeko Miyakawa
1,
Yushi Sakai
1,
Ryoko Nakayama
3,
Yumi Ito
4,
Mitsuhiko Hasebe
1,
Koji Kawaguchi
1 and
Yoshiki Hamada
1
1
Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Kanagawa, Japan
2
Department of Oral Hygiene, Tsurumi Junior College, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Kanagawa, Japan
3
Department of Pathology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Kanagawa, Japan
4
Department of Diagnostic Pathology, Tsurumi University Dental Hospital, Yokohama 230-8501, Kanagawa, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(3), 1191; https://doi.org/10.3390/ijms26031191
Submission received: 11 December 2024 / Revised: 25 January 2025 / Accepted: 26 January 2025 / Published: 30 January 2025
(This article belongs to the Special Issue Interactions Between Microbes and Hosts: Physiology, Pathology and Treatment)
Review Reports Versions Notes

Abstract

This study investigated the effects of the poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib, alone and in combination with cisplatin, on intestinal integrity, survival, and microbiome composition using a murine model. Statistical analyses were conducted using one-way analysis of variance with Bonferroni correction for multiple comparisons, considering p-values of <0.05 as statistically significant. Microbiome profiling was performed using Qiime 2 software. Histopathological and microbiome analyses revealed Olaparib’s protective effects on intestinal integrity, mitigating cisplatin-induced damage. The single administration of cisplatin caused significant histological damage, biochemical disruptions, and dysbiosis, characterized by an increase in pro-inflammatory microbiome, such as Clostridium_sensu_stricto_1, and a decrease in beneficial short-chain fatty acid (SCFA)-producing microbiome. Conversely, the single administration of Olaparib was associated with an increase in SCFA-producing microbiome, such as Lachnospiraceae NK4A136, and exhibited minimal toxicity. The combination administration showed complicated outcomes, as follows: reduced cisplatin-induced cytotoxicity and increased SCFA-producing microbiome ratios, yet the long-term effects revealed reduced survival rates in the cisplatin group and sustained weight gain suppression. These findings emphasize Olaparib’s potential in enhancing intestinal barrier integrity, reducing inflammation, and positively modulating microbiome diversity. However, the entangled pharmacodynamic interactions in the combination administration underscore the need for further investigation. The study highlights the potential of microbiome-targeted interventions in improving therapeutic outcomes for both cancer treatment and inflammatory bowel disease management.
Keywords: PARP inhibitor; Olaparib; cisplatin; microbiome; pyroptosis; survival; dysbiosis PARP inhibitor; Olaparib; cisplatin; microbiome; pyroptosis; survival; dysbiosis

Share and Cite

MDPI and ACS Style

Matsumura, M.; Fujihara, H.; Maita, K.; Miyakawa, M.; Sakai, Y.; Nakayama, R.; Ito, Y.; Hasebe, M.; Kawaguchi, K.; Hamada, Y. Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model. Int. J. Mol. Sci. 2025, 26, 1191. https://doi.org/10.3390/ijms26031191

AMA Style

Matsumura M, Fujihara H, Maita K, Miyakawa M, Sakai Y, Nakayama R, Ito Y, Hasebe M, Kawaguchi K, Hamada Y. Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model. International Journal of Molecular Sciences. 2025; 26(3):1191. https://doi.org/10.3390/ijms26031191

Chicago/Turabian Style

Matsumura, Mitsuki, Hisako Fujihara, Kanna Maita, Moeko Miyakawa, Yushi Sakai, Ryoko Nakayama, Yumi Ito, Mitsuhiko Hasebe, Koji Kawaguchi, and Yoshiki Hamada. 2025. "Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model" International Journal of Molecular Sciences 26, no. 3: 1191. https://doi.org/10.3390/ijms26031191

APA Style

Matsumura, M., Fujihara, H., Maita, K., Miyakawa, M., Sakai, Y., Nakayama, R., Ito, Y., Hasebe, M., Kawaguchi, K., & Hamada, Y. (2025). Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model. International Journal of Molecular Sciences, 26(3), 1191. https://doi.org/10.3390/ijms26031191

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop